Clinical Trials
5 trialsNCT07619521 2026-06-02
Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a, for Advanced Pancreatic Ductal Adenocarcinoma
National Cancer Institute (NCI)
Phase 1/2 Not yet recruiting
NCT01362803 2026-06-01
AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors
National Institutes of Health Clinical Center (CC)
Phase 1/2 Active not recruiting
NCT01089101 2026-05-13
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT01364051 2026-04-13
Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02407405 2026-03-05
MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting